Skip to content
TrialScanner

NCT05216510

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

Phase 1TerminatedTNXPLead

Registry record

Lead sponsor
Tonix Pharmaceuticals, Inc.
Conditions
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Primary completion
Sep 17, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05216510 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05216510: Assessment of Delayed-type... | TrialScanner